OraSure responds to Altai Capital, citing 40% TSR outperformance under CEO; $199M cash; product catalysts ahead

ORASURE TECHNOLOGIES INC

Total shareholder return outperformed peer median by ~40% during CEO Carrie Eglinton Manner's tenure (since June 2022).
Cash balance of $199M, no debt; $40M share repurchase program initiated in 2025 at avg price $2.85.
Gross margin improved 260bps over 3 years to 43%; SG&A reduced 37% to $73.8M; workforce cut ~40%.
Near-term catalysts: Colli-Pe urine collection device (~$0.5B TAM) and Sherlock CT/NG self-test (~$1.5B TAM).
Expects operating cash flow breakeven entering 2027; new products launching in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.